All In Biotech

Drug Trial Radar · NCT07011485

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

A Triple-Blind, Randomized, Efficacy and Tolerability Comparison Study of PDFE-2304 Topical Solution Versus Minoxidil 5% Topical Solution for the Treatment of Androgenic Alopecia (AGA).

Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

May 14, 2025

Primary completion

Aug 14, 2025

Study completion Sep 17, 2025

Sponsor

Lead sponsor
PDFE Pharma Innovations FZCOIndustry
Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).

Conditions

  • Alopecia, Androgenetic
  • Baldness
  • Androgenetic Alopecia (AGA)

Interventions

  • Minoxidil 5% Topical SolutionDrug

    Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

  • PDFE-2304 Topical SolutionDrug

    Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Target Area Hair Count (TAHC)Time frame: Baseline, Week 16 (Day 112)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Koppal Institute of Medical Sciences

    Koppal, Karnataka, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.